Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection by Hislop, Andrew D. et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/04/893/13 $5.00
Volume 195, Number 7, April 1, 2002 893–905
http://www.jem.org/cgi/content/full/195/7/893
 
893
 
Epitope-speciﬁc Evolution of Human CD8
 
 
 
 T Cell
Responses from Primary to Persistent Phases of
Epstein-Barr Virus Infection
 
Andrew D. Hislop, Nicola E. Annels, Nancy H. Gudgeon,
 
Alison M. Leese, and Alan B. Rickinson
 
CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
 
Abstract
 
Primary virus infection often elicits a large CD8
 
 
 
 T cell response which subsequently contracts
to a smaller memory T cell pool; the relationship between these two virus-specific populations
is not well understood. Here we follow the human CD8
 
 
 
 T cell response to Epstein-Barr virus
(EBV) from its primary phase in infectious mononucleosis (IM) through to the persistent carrier
state. Using HLA-A2.1 or B8 tetramers specific for four lytic cycle and three latent cycle
epitopes, we find marked differences in the epitope-specific composition of the T cell popula-
tions between the two phases of infection. The primary response is dominated by lytic epitope
specificities which are severely culled (and in one case extinguished) with resolution of the
acute infection; in contrast latent epitope specificities are less abundant, if present at all, in acute
IM but often then increase their percentage representation in the CD8 pool. Even comparing
epitopes of the same type, the relative size of responses seen in primary infection does not
necessarily correlate with that seen in the longer term. We also follow the evolution of pheno-
typic change in these populations and show that, from a uniform CD45RA
 
 
 
RO
 
 
 
CCR7
 
 
 
phenotype in IM, lytic epitope responses show greater reversion to a CD45RA
 
 
 
RO
 
 
 
 pheno-
type whereas latent epitope responses remain CD45RA
 
 
 
RO
 
 
 
 with a greater tendency to acquire
CCR7. Interestingly these phenotypic distinctions reflect the source of the epitope as lytic or
latent, and not the extent to which the response has been amplified in vivo.
Key words: Epstein-Barr virus • CD8
 
 
 
 T lymphocytes • infectious mononucleosis • kinetics • 
phenotype
 
Introduction
 
Primary virus infections both in mouse models and in man
are often accompanied by marked expansions of reactive
CD8
 
 
 
 T cells. In several viral systems it has been shown
that these expansions are indeed virus-specific and domi-
nated by cytotoxic reactivities against a relatively small
number of viral epitope peptides presented in the context
of host MHC class I molecules (1–8). As the acute infection
is brought under control and antigen load diminishes, the
great majority of these primary effectors die by apoptosis
and T cell numbers return to the normal range (9–11).
However, some virus-specific CD8
 
 
 
 T cells survive and en-
ter the memory pool where they subsequently persist and
from which they are able to reactivate when challenged ei-
ther by a second exogenous infection with a related virus
strain or, in the case of a naturally persistent agent, by a re-
crudescence of the existing infection.
The relationship between primary and memory CD8
 
 
 
 T
cell populations and the factors which determine selection
into memory remain poorly understood. Generally, studies
in murine models with agents such as lymphocyte chorio-
meningitis virus indicate that primary and memory virus-
specific populations are qualitatively similar in terms of the
relative prevalence of the different epitope-specific reactivi-
ties making up the whole response (1, 8, 12). This gave rise
to the notion that all components of the primary response
were equally culled, hence that clonal “burst size” at the
height of the acute infection determined the extent of repre-
sentation in memory (8, 13). Although changes in the mem-
ory repertoire could be induced by experimental rechallenge
in such model systems, these changes were detected as re-
finements of dominant T cell receptor usage within an
epitope-specific population rather than as shifts in the rela-
tive prevalence of different epitope reactivities (14–16).
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Prospective studies on human CD8
 
 
 
 T cell responses
during and after acute viral infection are as yet quite lim-
ited, but have been helped by the ability to identify
epitope-specific T cells in PBMC preparations either by
staining with HLA class I–peptide tetramers or by peptide-
induced synthesis of type I cytokines (17–19). In a recent
study, HIV-infected patients were screened using a large
panel of HIV epitope peptides in enzyme-linked immuno-
spot (Elispot)
 
*
 
 assays of interferon 
 
 
 
 release (20). Compari-
sons between cohorts of patients at different stages of infec-
tion suggested that the primary response is directed toward
a more limited range of epitopes than that seen in chronic
carriers. However, such apparent broadening of the re-
sponse with prolonged exposure to HIV could reflect the
diversification of antigenic challenge in vivo from this ge-
netically unstable agent. More interestingly prospective
studies on individual patients identified one HIV epitope-
specific reactivity which was consistently undetectable in
primary infection, even though the epitope was present in
the infecting viral strain, but did appear later (20).
The present work addresses these same issues in the con-
text of exposure to EBV, a genetically stable human 
 
 
 
-her-
pesvirus which can establish both virus productive (lytic)
and nonproductive (latent) infections in target B lympho-
cytes (21). Primary EBV infection is clinically manifest as
infectious mononucleosis (IM) and is characterized by a
massive expansion of activated CD45RO
 
 
 
CD8
 
 
 
 T cells.
We have shown, initially using ex vivo cytotoxicity assays
and subsequently HLA class I–peptide tetramer staining,
that a large fraction of this response is EBV-specific and re-
active to defined immunodominant epitopes, principally
drawn from the immediate early and some early proteins of
the lytic cycle (3, 22, 23). On the basis of staining with one
A2.1–epitope and one B8–epitope tetramer, it seemed that
individual lytic epitope reactivities could account for be-
tween 5 and 50% of the CD8
 
 
 
 T cell expansion in IM
blood. At the same time reactivities to certain latent cycle
epitopes, usually drawn from a subset of the virus-coded
nuclear antigens (EBNAs), were also detectable but, from
the evidence of staining with one B8–epitope tetramer,
only account for 1–3% of the CD8
 
 
 
 expansion (3). Inter-
estingly we noted that both types of reactivity were also
detectable, albeit at lower levels, in the blood of long-term
asymptomatic EBV carriers (24, 25). However, both there
and in the small number of post-IM patients studied (3),
numeric differentials between the two populations were
now less marked. Furthermore, in long term carriers the
two types of reactivity appeared to be phenotypically dis-
tinct in that lytic epitope-specific populations were hetero-
geneous in terms of CD45 isoform (RO versus RA) ex-
pression whereas latent epitope-specific populations were
uniformly RO
 
 
 
RA
 
 
 
 and often contained a higher propor-
tion of cells expressing CCR7 (25), a homing marker
which has been proposed to identify a “central memory”
 
(as opposed to an “effector memory”) T cell subset (26). It
was not clear, however, when these phenotypic differences
might arise and whether they were intrinsic to the two
types of epitope or rather reflected different levels of
epitope-driven expansion in vivo. This prompted the
present study in which we have increased the number of
informative A2.1- and B8-restricted lytic and latent cycle
epitopes and followed the evolution of these responses,
both in terms of cell number and cell phenotype, for a pe-
riod of between 1 and 14 yr from the point of acute pri-
mary infection.
 
Materials and Methods
 
Donors.
 
Patients in the acute phase of IM (within 7 d of the
onset of symptoms) were identified on clinical grounds and diag-
nosis confirmed by high leukocyte counts and by heterophile an-
tibody positivity. Heparinized blood (30–60 ml/patient) was used
to prepare PBMCs and aliquots of the cells cryopreserved; pa-
tients with the HLA-A2.1 and/or B8 allele were identified by ge-
notype assay. Individual patients selected for the study were bled
on up to six subsequent occasions between 3 mo and 14 yr later;
all patients had shown a complete resolution of disease symptoms
within 3–4 wk of the initial acute phase sample being taken.
For some comparative experiments, healthy laboratory donors
(HLA-A2.1 and/or B8-positive) were sampled on at least two
occasions; all had been EBV carriers for at least 5 yr and all had
no prior history of IM.
 
T Cell Cloning and Epitope Identification.
 
CD8
 
 
 
 T cell clones
were generated from the blood of selected HLA-A2.1–positive
IM patients by limiting dilution cloning of PBMCs on feeder
cells in interleukin 2-conditioned medium as described (23).
Clones with specific cytotoxicity against EBV antigens were
identified in standard 5 h chromium release assays by testing on
HLA-A2.1–matched EBV-transformed B lymphoblastoid cell
line (LCL) targets preinfected with recombinant vaccinias ex-
pressing one of a series of individual EBV (B95.8 strain) lytic or
latent cycle antigens, again using previously published methods
(27). Where necessary, the epitope specificity of the clones was
identified first by testing on a panel of peptides (15 mers overlap-
ping by 10) representing the primary sequence of the relevant
EBV antigen (B95.8 strain), and then by testing shorter peptides
within the 15-mer of interest using targets preexposed to a range
of peptide concentrations.
 
Peptides and HLA Class I Tetramers.
 
The following EBV-
epitope peptides were used in this study: the A2.1-restricted
epitopes 
 
GLC
 
TLVAML derived from the lytic cycle protein
BMLF1 (23,28), 
 
YVL
 
DHLIVV derived from the lytic cycle pro-
tein BRLF1 (29), 
 
TLD
 
YKPLSV from the lytic cycle protein
BMRF1 (this study) and 
 
CLG
 
GLLTMV derived from the latent
cycle protein LMP2 (30). The B8-restricted epitope peptides used
in this study were 
 
RAK
 
FKQLL derived from the lytic cycle pro-
tein BZLF1 (31) and 
 
FLR
 
GRAYGL (32) and 
 
QAK
 
WRLQTL
(33) both derived from the latent cycle protein EBNA3A. The
nomenclature for epitope peptides has been abbreviated to the first
three amino acids throughout this text. The peptides were pur-
chased from Alta Biosciences and dissolved in DMSO (Fisher
Chemicals) to a concentration of 5 mg/ml and diluted to appro-
priate concentrations in RPMI-1640 immediately before use.
HLA class I/peptide tetramers were synthesized as described
previously (17). Briefly, HLA-A2.1 recombinant heavy chains
containing the Bir A biotinylation motif were refolded with ei-
 
*
 
Abbreviations used in this paper:
 
 EBNA, EBV nuclear antigen; Elispot, en-
zyme-linked immunospot; IM, infectious mononucleosis; LCL, B lym-
phoblastoid cell line. 
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ther of the peptides GLC, YVL, TLD, or CLG, while HLA-B8
recombinant heavy chains were refolded in the presence of ei-
ther FLR, QAK, or RAK peptide. After biotinylation with Bir
A (Avidity) the refolded heavy chains were purified on a Super-
dex G75 HiLoad 26/60 prep grade FPLC column (Amersham
Pharmacia Biotech) followed by further purification on a Mono
Q anion exchange FPLC column (Amersham Pharmacia Bio-
tech). The purified monomers were tetramerized by addition of
streptavidin R-phycoerythrin (Molecular Probes) at a molar ratio
of 4:1 respectively
 
Tetramer Staining Assays.
 
Staining of lymphocytes was under-
taken by incubating the cells with a pretitrated concentration of
tetramer (
 
 
 
0.5 
 
 
 
g/ml) at 37
 
 
 
C for 15 min. The cells were then
stained for surface markers by incubation on ice with saturating
amounts of anti–human CD8 mAbs conjugated to Tricolor (Cal-
tag Laboratories) and, for phenotyping experiments, FITC-con-
jugated anti–human mAbs specific for either CD45RA (Beckman
Coulter) or CD45RO (Dako). To detect CCR7 expression in
phenotype studies, tetramer-stained cells were incubated with an
anti–human CCR7 mAb (a gift from Millennium Pharmaceuti-
cals Inc., Cambridge, MA). Binding of the CCR7-specific mAb
was detected by incubation with goat anti–mouse heavy-light
chain-specific FITC-labeled antibody (Southern Biotechnology
Associates, Inc.). Free anti–mouse binding sites were subse-
quently blocked by incubation with normal mouse serum and the
cells then stained with the Tricolor-conjugated anti–human CD8
antibody (Caltag Laboratories). These stained cells were then an-
alyzed on an Epics flow cytometer (Beckman Coulter). Note that
color compensation between the different fluorochromes was set
using single fluorochrome-stained cells from the same test popu-
lation as described previously (34).
 
Results
 
Identification of A2.1-restricted Lytic Cycle Epitopes by IM
CD8
 
 
 
 T Cell Cloning.
 
In an initial series of experiments,
CD8
 
 
 
 T cell clones were established by limiting dilution of
PBMCs cryopreserved from HLA-A2.1–positive IM pa-
tients, and screened for EBV-specificity in cytotoxicity as-
says on A2.1-positive LCL targets expressing individual
EBV proteins from recombinant vaccinia vectors. Fig. 1 A
presents data from one such patient, IM119, to illustrate
each of the three types of CD8
 
 
 
 T cell reactivity typically
seen in such experiments. The most abundant reactivity
exemplified by clone 5 was directed against the immediate
early lytic cycle protein BRLF1. Subsequent screening on
peptide-loaded targets narrowed this response down to a
9-mer epitope YVLDHLIVV (designated YVL) within the
BRLF1 sequence; this same epitope was independently
identified in a recent study of T cell clones derived from
synovial lymphocytes isolated from chronic arthritis pa-
tients (29). A second less abundant reactivity exemplified
by clone 35 recognized the BMLF1 early lytic cycle pro-
tein and mapped to the previously described 9-mer epitope
GLCTLVAML (designated GLC) (23, 28). A third reactiv-
ity, detected in a small number of IM119-derived clones
exemplified by clone 136, mapped to another early lytic
protein BMRF1 and was identified in peptide sensitization
assays as recognizing a novel 9-mer epitope TLDYKPLSV
(designated TLD). In the study of IM119 we never de-
tected A2-restricted CD8
 
 
 
 T cell clones recognizing any of
the EBV latent cycle proteins in vaccinia assays, nor when
we deliberately screened clones on the peptide CLG-
GLLTMV (designated CLG), a 9-mer derived from the la-
tent membrane protein LMP2; although subdominant
among latent cycle epitopes, CLG nevertheless represents
one of the strongest known targets of A2-restricted latent
cycle memory in healthy virus carriers (35).
To check that the in vitro cloning results were indeed
reflecting reactivities present within the initial PBMC pop-
Figure 1. Specificity of CD8  CTL clones isolated from an IM patient
(IM119) by limiting dilution cloning, and quantitation of these responses
in PBMCs by flow cytometry. (A) HLA-A2.1–restricted CD8  clones
were tested in cytotoxicity assays against autologous LCL targets that had
either been infected with recombinant vaccinia (v) viruses expressing
EBV lytic cycle antigens BRLF1, BMLF1, or BMRF1 (or with the con-
trol vaccinia vTK ) or been sensitized with peptides YVL, GLC, or TLD
representing minimal A2.1-restricted epitopes contained within these
proteins. Effector/target ratios used were 2:1, and cytotoxicity is ex-
pressed as percentage of specific lysis observed in a standard 5 h chromium
release assay. (B) Acute IM PBMCs from IM119 were stained with PE-
conjugated HLA-A2.1 tetramers containing either the YVL, GLC, or
TLD peptide, and subsequently with Tricolor-conjugated antibodies to
CD8. Percentage values refer to the percentage of CD8  T cells that
stained with the tetramer (top right quadrant). 
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ulation, we constructed A2.1 tetramers for each of the
above lytic epitopes and for the CLG latent epitope. Fig. 1
B shows the data obtained by staining another aliquot of
PBMCs from the acute phase bleed of IM patient 119 (de-
noted IM119.1). This shows that 7.3% of the highly ex-
panded CD8
 
 
 
 T cells in this patient stained with the A2.1–
YVL tetramer, 3.6% with the A2.1–GLC tetramer and
0.6% with the A2.1–TLD tetramer. By contrast, there was
no significant staining with the A2.1–CLG tetramer (data
not shown).
 
Comparison of A2.1 Epitope-specific Frequencies in Acute IM
Patients and Long-term Carriers.
 
To further characterize the
CD8
 
 
 
 T cell response to the novel YVL and TLD epitopes
as well as to GLC and CLG, this same panel of tetramers
was used to stain PBMCs from another 8 A2.1-positive
acute IM patients and from 12 A2.1-positive long-term
EBV carriers. The results from the two sets of donors, sum-
marized in Table I, are strikingly different. In the acute IM
patients all three lytic epitope-specific reactivities were de-
tectable with the YVL response (accounting for up to
33.6% CD8
 
 
 
 T cells) being the most abundant in 7/9 cases,
followed either by GLC (up to 11.8% CD8
 
 
 
 T cells) or by
TLD (up to 6.1% CD8
 
 
 
 T cells) as the next most abundant
response; however, only one of these patients showed a de-
tectable response to the latent CLG epitope. By contrast, in
long-term EBV carriers the GLC response (up to 2.2%
CD8
 
 
 
 T cells) was always the most abundant followed by a
weaker YVL response detectable in 9/12 donors and by a
very weak TLD response in only 2/12 donors; interest-
ingly, most (9/12) long-term carriers also showed clear ev-
idence of a CLG-specific population.
 
Prospective Studies of the Response to A2.1-restricted Epi-
topes.
 
In light of these findings we performed prospective
studies on all nine A2.1-positive IM patients in Table I,
samples being taken on up to four further occasions over a
period of 14 yr in one case, 5 yr in two cases, and 1–2 yr
for the rest. This revealed differences between the kinetics
of the lytic epitope responses, which consistently peaked in
acute IM and then fell substantially, and the latent epitope
response which was usually undetectable in IM but often
appeared in later bleeds. To illustrate these trends, FACS
 
®
 
profile data from two patients are shown in Fig. 2. For
IM81 (Fig. 2 A) primary responses to the YVL and GLC
epitopes were very large, accounting for 33.6 and 11.8% of
the CD8
 
 
 
 T cell pool in the acute disease, but both had
stabilized at 
 
 
 
1% CD8
 
 
 
 T cells by 30 mo after infection.
In IM146 (Fig. 2 B), primary responses to these two
epitopes were 10-fold lower than in IM81 yet both were
again culled down to 0.4–0.7% of the CD8
 
 
 
 pool. In both
patients the TLD response became undetectable (even
though in IM146 it had exceeded both the YVL and GLC
responses during the acute phase), while over the same pe-
riod both patients showed delayed development of a CLG-
specific CD8
 
 
 
 population in the blood.
The results of these prospective studies on A2.1-restricted
epitope responses for all nine patients are summarized in
Table II. These data confirm the generality of the trends
outlined above. Thus, there was a marked fall in the per-
centage representation of lytic epitope-specific T cells in
the CD8
 
 
 
 pool in 7/9 patients for the GLC response and
in all nine patients for the YVL and TLD responses; indeed
the TLD response, which was regularly observed in acute
primary infection, fell below detectable levels in 7/9 cases
after IM. These falls in lytic epitope responses were signifi-
cant whether the data for each epitope were considered in-
dividually or combined into a single model (see Table II
legend). By contrast, in four of the five patients who
mounted a response to the latent CLG epitope, this was
undetectable in acute IM and only appeared in later bleeds.
In addition, retrospective analysis of stored samples from
five other HLA-A2.1–positive patients where GLC-spe-
cific T cell representation in the CD8
 
 
 
 T cell pool had
fallen from 4–10% in acute IM to 0.3–1.1% in a later bleed
(34) again showed that the CLG response, where detect-
able, was always delayed (data not shown).
These findings demonstrate the very significant differ-
ences that exist between the composition of CD8
 
 
 
 T cell
responses found in the blood in acute primary infection
versus the subsequent virus carrier state. Moreover, such
differences do not only relate to comparisons between lytic
and latent epitopes since in two cases, IM 13 and IM 79,
 
Table I.
 
Percentage of CD8
 
 
 
 T Cells Staining with A2.1
Epitope Tetramers
 
Lytic
epitopes
Latent
epitope
Donor YVL GLC TLD CLG
IM 13.1 20.3 0.8 1.6 0
IM 79.1 29.0 0.7 6.1 0.1
IM 81.1 33.6 11.8 1.0 0
IM 113.1 2.7 1.9 0.4 0
IM 119.1 7.3 3.6 0.6 0
IM 123.1 9.8 6.5 0.5 0
IM 130.1 4.1 0.7 0.3 0
IM 140.1 4.1 7.3 1.1 0
IM 146.1 2.9 1.0 2.7 0
CM 0.1 2.2 0 0.05
CW 0.3 0.9 0 0.1
DA 0.2 0.4 0 0.1
DW 0.7 2.2 0.1 0.2
JL 0.2 1.5 0 0
JSt 0.1 0.5 0 0.2
LH 0.05 0.2 0 0.1
MG 0.3 0.8 0.05 0
NB 0 0.5 0 0.1
NG 0.1 0.5 0 0.1
SL 0 0.3 0 0
SY 0 1.3 0 0.3 
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there are also clear differences in the response to individual
lytic epitopes. In both of these cases the YVL response was
clearly dominant in the primary (20–29% CD8
 
 
 
 T cells)
followed by TLD, with an unusually low response (0.7–
0.8% CD8
 
 
 
 T cells) to GLC. These individuals showed
marked culling of the YVL- and TLD-specific populations
but sparing of the weak GLC response such that, despite
their initial differences, the YVL and GLC reactivities fin-
ished up at roughly equivalent levels in the late post-IM
bleeds. It is also interesting to compare the data from the fi-
nal post-IM bleeds in all nine patients in Table II
 
 
 
with the
corresponding values from healthy long-term virus carriers
in Table I. This shows that the range of A2.1 epitope reac-
tivities established post-IM becomes similar to that seen in
long-term carriers (YVL
 
 
 
, GLC
 
 
 
, TLD
 
 
 
, CLG
 
 
 
) but that
post-IM patients have significantly higher YVL responses
both in absolute terms and in relation to the coresident
GLC response (
 
P
 
 
 
 
 
 0.008 and 
 
P
 
 
 
 
 
 0.005, respectively,
two-sample Wilcoxon test).
 
Prospective Studies of the Response to B8-restricted Epi-
topes.
 
To extend these prospective studies to lytic and
latent epitope-specific responses restricted through a differ-
ent HLA allele, we followed five HLA-B8–positive IM pa-
tients for a period of 14 mo to 5 yr. Note that two of these
patients, IM130 and IM140, were both HLA-A2– and B8-
positive and so are involved in both studies. Here we mon-
Figure 2. Evolution of the
CD8 T cell response to the
A2.1-restricted epitopes YVL,
GLC, TLD, and CLG in patients
sampled during and after acute
IM. (A) PBMCs cryopreserved
from IM81 during acute IM
and 30 and 54 mo later and (B)
PBMCs cryopreserved from
IM146 during acute IM and 4
and 12 mo later were stained
with individual A2.1 epitope tet-
ramers and with anti-CD8. Re-
sults for each time point are pre-
sented as in Fig. 1 B. 
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itored responses to the B8 epitope RAKFKQLL (RAK)
from the immediate early lytic antigen BZLF1 and to two
B8 epitopes FLRGRAYGL (FLR) and QAKWRLQTL
(QAK) both derived from the latent cycle antigen
EBNA3A. Note that these peptides are among the stron-
gest of all known EBV lytic and latent cycle epitopes re-
spectively as judged by epitope-specific T cell numbers in
the blood of healthy carriers (24).
In this series of patients, the lytic epitope response was
again numerically dominant during the acute primary in-
fection and was culled thereafter while the latent epitope
responses, although now clearly detectable in acute IM,
again often increased percentage representation in the
CD8
 
 
 
 T cell pool in later bleeds. Fig. 3 presents some of
the FACS
 
®
 
 profile data from one such patient, IM 141 who
was studied in acute IM and on a total of four subsequent
occasions up to 14 mo later. The RAK response consti-
tuted 31.2% of all CD8
 
 
 
 T cells in the primary bleed; this
value fell within 3 mo to 7.9% and stabilized at a slightly
lower level thereafter. By contrast the latent FLR and
QAK epitope responses were much smaller in the acute
phase (2.5% and 0.7% CD8
 
 
 
 T cells, respectively) but both
had increased their percentage representation at 3 mo.
Thereafter, the QAK response followed the more typical
course for a B8 latent epitope in stabilizing at a slightly
lower level whereas in this particular patient the FLR re-
sponse slowly increased such that by 14 mo it constituted
7.6% of all circulating CD8
 
 
 
 T cells and was even more
abundant than the RAK response.
Table III summarizes all of the prospective data from the
five B8-positive IM patients studied. These results again
emphasize the generally different kinetics of lytic versus la-
tent epitope responses in that percentage representation of
the RAK response in the CD8
 
 
 
 pool always fell post-IM,
though at different rates in different patients, whereas FLR-
and QAK-response representation rose post-IM in 4/5 and
in 3/5 cases, respectively. Combining these findings with
equivalent RAK and FLR epitope data from the three pa-
tients in our original study (3), the fall in percentage repre-
sentation of the lytic epitope response over time post-IM is
clearly significant (
 
P
 
 
 
 
 
 0.008) whereas the latent epitope
 
Table II.
 
Prospective Study of A2.1 Epitope Response
 
Lytic
epitopes
Latent
epitope
Donor
(time post-IM) YVL GLC TLD CLG
13.1 20.3 0.8 1.6 0
13.5 (14 yr) 1.1 0.8 0 0
79.1 29.0 0.7 6.1 0.1
79.2 (30 mo) 1.9 0.4 0.4 0.1
79.3 (60 mo) 2.4 1.4 1.0 0.2
81.1 33.6 11.8 1.0 0
81.2 (30 mo) 0.9 0.4 0 0.05
81.3 (36 mo) 1.2 0.3 0 0.3
81.4 (44 mo) 1.2 0.3 0 0.1
81.5 (54 mo) 1.1 0.4 0 0.2
113.1 2.7 1.9 0.4 0
113.2 (14 mo) 0.2 0.6 0.05 0.05
113.3 (17 mo) 0.2 0.5 0 0.1
113.4 (25 mo) 0.2 0.3 0 0.1
119.1 7.3 3.6 0.6 0
119.2 (4 mo) 1.3 1.4 0.05 0
119.3 (10 mo) 0.5 0.8 0 0
123.1 9.8 6.5 0.5 0
123.2 (2 mo) 4.8 2.4 0.1 0
123.3 (11 mo) 1.8 0.9 0.1 0
130.1 4.1 0.7 0.3 0
130.2 (5 mo) 0.2 0.2 0 0
130.3 (12 mo) 0.1 0.2 0 0
130.4 (20 mo) 0.1 0.1 0 0
140.1 4.1 7.3 1.1 0
140.2 (3 mo) 1.9 4.0 0.8 0.3
140.3 (8 mo) 1.1 2.5 0.2 0.3
140.4 (10 mo) 1.1 2.3 0.0 0.1
140.5 (14 mo) 1.0 1.5 0.0 0.3
146.1 3.1 1.0 3.3 0
146.2 (4 mo) 0.7 0.3 0.7 0.3
146.3 (12 mo) 0.7 0.4 0 0.4
The lytic epitope responses decrease significantly over time. (YVL: 
 
P 
 
 
 
0.0008, GLC: 
 
P 
 
  
 
0.02, TLD: 
 
P 
 
  
 
0.002). These figures are the result of
modeling each of the lytic epitopes as log(response) using SAS PROC
MIXED with a random effect for intercept and with fixed and random
effects for time. Combining these into a single model suggests different
rates of fall between epitopes (
 
P 
 
  
 
0.003 for fixed epitope time interaction
effect). The latent epitope response shows no such effect.
Figure 3. Evolution of the CD8 T cell response to the B8-restricted
epitopes RAK, FLR, and QAK in patient IM141. PBMCs cryopreserved
during acute IM and 3 and 14 mo later were stained with the individual
B8 epitope tetramers and with anti-CD8. Results for each time point are
presented as in Fig. 1 B. 
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response shows no significant time effect (
 
P
 
 
 
 
 
 0.73). Table
III also highlights the fact that within an individual donor,
the kinetics of the FLR and QAK latent epitope responses
do not always run strictly in parallel; the best examples of
this are IM141 (Fig. 3, described above) and IM70 where
the FLR response followed a typical pattern of increased
representation over time while the coresident QAK re-
sponse fell post-IM.
 
Cell Phenotype Changes with Evolution of the Lytic and La-
tent Epitope Responses.
 
In a recent study of long-term vi-
rus carriers, we noted a clear distinction between lytic and
latent epitope-specific populations in their expression of
certain differentiation markers. Thus, latent epitope-spe-
cific T cells mostly lay within the CCR7
 
 
 
 “central mem-
ory” subset and were uniformly CD45RO
 
 
 
CD45RA 
whereas lytic epitope-specific populations were often more
skewed toward the CCR7  “effector memory” phenotype
and contained some CD45RA CD45RO  cells (25). In
the present work we sought to determine if and when such
differences became apparent during the evolution of these
responses in IM/post-IM patients, and whether they cor-
related with the source of the epitope per se or with the
level of expansion that had occurred within the epitope-
driven response.
Fig. 4 shows representative data from one such analysis
involving the HLA-A2.1–positive patient IM79 sampled at
the time of primary infection (IM79.1) and 5 yr later
(IM79.3). On each occasion PBMCs were stained with a
PE-labeled tetramer, Tricolor-labeled anti-CD8 mAb, and
a FITC-labeled mAb to the third phenotypic marker; the
top FACS® profiles show tetramer versus CD8 staining on
total PBMCs, and the remaining profiles show tetramer
versus third marker staining after gating on the CD8high
PBMC fraction. During primary infection in IM79, the re-
sponse to the lytic cycle epitope YVL was numerically
dominant (29% CD8  T cells) and was almost entirely
CD45RA CD45RO  and CCR7 , a phenotype consis-
tent with the status of activated effector cells. In the late
post-IM bleed, the YVL-specific population was numeri-
cally much smaller, heterogeneous in terms of CD45RA
and RO expression, with a minority (32%) of cells having
acquired CCR7. Interestingly this same pattern of pheno-
typic change was also observed in the individual’s responses
to the two other A2.1-restricted lytic cycle epitopes, GLC
and TLD, even though these responses were less dramati-
cally expanded during primary infection (data not shown).
IM79 was selected for study because a small primary re-
sponse to the CLG latent epitope was detectable in this
particular individual. As shown in Fig. 4 B, this small pri-
mary population was likewise CD45RA , CD45RO ,
and CCR7  whereas in the late bleed the CLG-specific
population, now constituting a slightly larger proportion of
CD8  T cells, was still uniformly CD45RA CD45RO 
but the majority (64%) of cells had acquired CCR7. This
implies that, with sufficiently long follow-up, lytic and la-
tent epitope-specific T cell populations in the blood of
post-IM patients adopt the distinct phenotypic patterns al-
ready noted in long-term carriers. This was in fact con-
firmed when we studied late blood samples from three
other HLA-A2.1–positive individuals IM7, IM61, and
IM69 who were known to have had serologically and clin-
ically confirmed primary infections respectively 14, 5, and
4 yr earlier. As shown in Fig. 5 A, all three contained CLG
epitope-specific populations in the blood that, when com-
pared with their YVL- and GLC-specific populations,
were more strongly polarized toward a CD45RO RA 
phenotype and tended to contain a higher percentage of
CCR7  cells.
We subsequently performed a prospective phenotypic
analysis on three IM patients from the present series
(IM140, 141, and 146) who had been sampled during the
acute disease and on 2–4 further occasions over the next
12–14 mo. The results are presented in Fig. 5 B as graphs
showing the percentage of tetramer-positive cells at each
time point which expressed the CD45RA, CD45RO, and
Table III. Prospective Study of B8-restricted Response
Lytic
epitope
Latent
epitopes
Donor
(time post-IM) RAK FLR QAK
53.1 12.6 3.3 0.3
53.2 (8 mo) 1.7 1.2 0.5
53.3 (15 mo) 2.0 1.8 0.4
70.1 32.4 0.2 2.0
70.2 (8 mo) 7.7 1.7 0.3
70.3 (38 mo) 2.1 0.5 0.1
70.4 (48 mo) 1.7 0.7 0.2
70.5 (55 mo) 2.1 0.7 0.2
70.6 (64 mo) 2.6 0.7 0.2
130.1 10.7 0.5 1.8
130.2 (5 mo) 1.5 0.4 1.5
130.3 (12 mo) 1.8 0.6 0.9
130.4 (21 mo) 0.57 0.2 0.3
140.1 24.6 0.3 0.9
140.2 (3 mo) 15.9 0.9 2.1
140.3 (8 mo) 9.6 0.8 1.2
140.4 (10 mo) 9.0 0.6 0.7
140.5 (14 mo) 10.0 0.7 0.7
141.1 31.2 2.5 0.7
141.2 (3 mo) 7.9 4.9 1.1
141.3 (8 mo) 3.9 5.7 0.8
141.4 (10 mo) 4.1 5.4 0.5
141.5 (14 mo) 5.2 7.6 0.6900 Evolution of EBV-specific CD8  T Cell Response
CCR7 markers. Patient IM140 is particularly instructive in
that this individual was both HLA-A2.1– and B8-positive,
allowing us to monitor the coincident responses to all
seven epitopes. The results clearly show that in this patient
there was a very marked change in all four lytic epitope re-
sponses with 70–90% cells moving from a CD45RO  phe-
notype in acute IM to a CD45RA  phenotype within 3
mo; this was maintained over the duration of the study
with only  10% of the cells acquiring CCR7. Interest-
ingly, the most marked reversion to RA  status was seen in
the TLD response, which was numerically the smallest of
all four lytic epitopes responses and the one which became
undetectable beyond the 8 mo bleed. By contrast, the three
latent epitope-specific responses in IM140, including one
(the QAK response) which in acute IM had been almost as
large as that seen to TLD, all showed a much lower pro-
portion of cells (20–40%) switching from RO  to RA 
status; these predominantly RO  populations showed a
consistent increase in the proportion of cells with the
CCR7 central memory marker to a value of 30–50% by 14
mo post-IM.
The two other patients studied in detail, IM141 (HLA-
B8–positive) and IM146 (HLA-A2.1–positive) showed
similar patterns of results, albeit with less dramatic differ-
ences between lytic and latent epitope responses (Fig. 5 B).
In these cases, the lytic epitope-specific populations (RAK
for IM141; YVL, GLC, and TLD for IM146) had switched
to become 40–60% CD45RA  within 3–4 mo of the acute
disease, a change that was maintained at least beyond the
first year, whereas latent epitope responses (FLR, QAK
for IM141; CLG for IM146) remained predominantly
CD45RO RA  again with a trend toward greater acquisi-
tion of CCR7. It was interesting to note that the unusually
large FLR-specific population that eventually outnum-
bered the RAK-specific population in later bleeds from
post-IM patient 141 (see Table III) nevertheless remained
distinct from it in terms of CD45RA/RO status.
Discussion
EBV provides one of the most instructive viral systems
in which to study the evolution of CD8  T cell responses
in man. Primary infection, at least as seen in adolescence, is
frequently manifest as acute IM and the CD8  lymphocy-
tosis associated with this disease is largely composed of
EBV-specific T cells constituting the primary virus-
induced response (3, 10, 34, 36, 37). Resolution of the
acute infection is accompanied by a dramatic culling of the
activated CD8  T cell population and restoration both of
circulating lymphocyte counts and of the CD4/CD8 ratio
back into the normal range (38, 39). Nevertheless, a small
number of EBV-specific CD8  T cells survive and are
maintained for life thereafter at low but apparently stable
levels (24, 40, 41). We were interested to compare the
composition of these EBV-specific populations given the
notion, arising from work in mouse model systems with
Figure 4. Analysis of EBV epitope-spe-
cific CD8  T cells for CD45RA,
CD45RO, and CCR7 status in patient
IM79 during acute IM and 50 mo later.
Cryopreserved PBMCs were stained with
either the A2.1/YVL tetramer (A) or with
the A2.1/CLG tetramer (B) followed by
anti-CD8 antibody and an antibody against
a third marker. The top flow cytometric
profiles show CD8 versus tetramer staining:
percentage values refer to the percentage of
CD8  cells that stained with tetramer. The
lower three profiles show tetramer staining
versus staining for the third marker
(CD45RA, CD45RO, CCR7) after gating
the analysis on CD8  cells; percentage val-
ues refer to the percentage of tetramer-posi-
tive cells staining for the marker in question.901 Hislop et al.
nonpersistent agents, that the “burst size” of an epitope-
specific CD8  T cell response at the time of primary infec-
tion is the principal determinant of its later representation
in memory (8, 13). The most important conclusion from
the present work is that the EBV-specific CD8  T cell
populations seen during primary infection and subse-
quently during asymptomatic viral persistence are qualita-
tively distinct; recent studies using a different methodology
broadly support this view (42,43). Such results are clearly
inconsistent with a simple “burst size” model.
One important distinction between the present work
and the mouse model systems referred to above is the fact
that EBV persists in the immune host, although at viral
loads 103–104-fold lower than observed during primary in-
fection (44). Hence the virus-specific CD8  T cells found
in the host long after primary infection, conventionally re-
ferred to as the “memory” population, have been main-
tained in the context of a chronic low grade antigenic
challenge. It is worth noting that there have been sugges-
tions of changes in the composition of human CD8  T
cell responses between acute and chronic phases of infec-
tion with other pathogens such as HIV and hepatitis C vi-
rus (20, 45–47). However, it is difficult to interpret such
data given that these viruses are genetically unstable and
continue to generate new antigenic variants in vivo. By
contrast EBV, a genetically stable herpesvirus, provides an
invariant antigenic challenge.
The clearest illustration of qualitative differences be-
tween the CD8  T cell response seen in primary versus
persistent EBV infection comes from comparison of lytic-
epitope and latent-epitope specificities. In our original
study, B8–RAK and B8–FLR tetramer staining on three
patients sampled at acute IM and at one point 2–3 yr later
first raised the possibility that the numerically larger re-
sponses to the RAK lytic cycle epitope might be dispropor-
tionately culled (3). The present work demonstrates that
this is indeed the case, sampling patients on more occasions
and comparing the B8–RAK response with responses
against two latent B8-epitopes, FLR and QAK. More im-
portantly the work shows that the kinetics of the lytic and
latent epitope responses are distinct. Thus, the RAK re-
sponse was numerically dominant in every case at primary
Figure 5. Analysis of CD45RA, CD45RO, and CCR7 expression on EBV epitope-specific CD8 T cells. (A) Cryopreserved PBMCs from A2.1-pos-
itive donors that had had IM up to 14 yr previously were stained with appropriate A2.1 epitope tetramers, followed by antibodies specific for CD8 and
for the third marker in question. Results are expressed as the percentage of CD8-positive tetramer-positive cells staining for each marker and are shown
for two lytic cycle epitopes, YVL ( ) and GLC ( ), and for the latent cycle epitope CLG ( ). (B) PBMCs cryopreserved from IM patients 140 (A2.1,
B8-positive), 141 (B8-positive), and 146 (A2.1-positive) during acute IM and subsequently on occasions up to 14 mo later were stained with appropriate
A2.1 and/or B8 epitope tetramers, with anti-CD8 and with antibodies to the third marker in question (CR45RA, CD45RO, and CCR7). The percent-
age of CD8-positive, tetramer-positive cells staining for each marker was determined and plotted over time for each donor. Results are shown for four
lytic cycle epitope A2/YVL ( ), A2/GLC ( ), A2/TLD ( ), B8/RAK ( ) and for three latent cycle epitopes A2/CLG ( ), B8/FLR ( ) and B8/QAK
( ). †Denotes an A2/TLD-specific population which became undetectable after the last time point shown. The star denotes the appearance of an A2/CLG-
specific population which was undetectable in acute IM.902 Evolution of EBV-specific CD8  T Cell Response
infection and its percentage representation in the circulat-
ing CD8  T cell pool fell by 2.5 to 20-fold thereafter. In
contrast, the FLR and QAK responses, though always de-
tectable in primary infection, had usually increased their
percentage representation when assayed 3–8 mo later and
thereafter reached a stable level often not too different from
that seen in primary infection. As a consequence, the sizes
of the lytic and latent epitope-specific pools became much
closer over time. These patterns were even clearer from the
work with the HLA-A2.1–restricted responses where T
cells reactive for each of three lytic cycle epitopes (YVL,
GLC, and TLD) were always detectable in primary infec-
tion at values ranging from 0.3–33% of the CD8  T cell
pool whereas T cells reactive to the latent cycle CLG
epitope were undetectable in all but one case. After IM, the
lytic epitope responses almost always fell whereas the CLG
response rose to detectable levels in 4/9 cases (where ex-
amined, within 3 mo of primary infection) and stabilized
thereafter. Although this detailed prospective study of
A2.1-restricted responses included just one latent cycle
epitope, we believe that the CLG results are generally rep-
resentative of subdominant latent cycle responses. Thus, we
have never detected A2.1-restricted responses to two addi-
tional subdominant latent epitopes, LLW and FLY, in stud-
ies on acute IM patients (data not shown) yet these reactiv-
ities often become detectable in post-IM bleeds just as they
are in the blood of healthy virus carriers (35). The delayed
appearance of the CLG-specific response after primary
EBV infection resembles that recently observed for an HIV
epitope in the context of primary HIV infection (20).
It is of course arguable that the kinetics of the lytic and
latent epitope responses differ because these epitopes are
likely presented by different cells in separate anatomical lo-
cations. Such a phenomenon has been reported in studies
of mouse T cell responses to the murine  -herpesvirus
MHV-68 where, between the primary and persistent
phases of infection, the dominant CD8  reactivity switches
from an epitope expressed in lung epithelium to an epitope
preferentially expressed in B cells (7). During the early
stages of EBV infection of the naive host, there is local rep-
lication of orally transmitted virus in the oropharynx
though the identity of the permissive cell type (epithelial or
B lymphoid) remains in doubt (48–52). This replicative
phase is assumed to precede the virus-driven expansion of
latently infected B cells that can be seen in IM tonsillar
lymphoid tissues (49, 50). However, the actual sequence of
the above events is not known, and certainly at the height
of IM both types of infection are well established (21). In
view of the present results, it will be important to monitor
levels of virus replication in the oropharynx and latent in-
fection in the B cell pool in the immediate aftermath of IM
to determine whether changes in antigenic load correlate
with the different T cell response patterns.
However, such arguments cannot explain another fea-
ture of the present results, which is that responses directed
against the A2.1-restricted lytic cycle epitopes YVL, GLC,
and TLD can also show different kinetics even though the
source antigens (BRLF1, BMLF1, and BMRF1 respec-
tively) are all coexpressed in the same cells very close to the
initiation of lytic cycle(21). Thus, the YVL response is usu-
ally numerically dominant in acute IM and is consistently
culled, as is the GLC response when its initial numbers are
relatively high. However, in patients such as IM13 and
IM79 (Table II) where the primary GLC response is low,
its percentage representation in the CD8 pool remains rela-
tively stable post-IM; consequently in such cases the YVL/
GLC ratio changes dramatically over time. By contrast the
TLD response, which is usually low in acute IM, is consis-
tently culled and almost always falls below the level of de-
tection. Indeed the absence of TLD reactivities in post-IM
patients (Table II) and also in long term carriers (Table I)
helps to explain why earlier studies of A2.1-restricted re-
sponses in EBV carriers have not identified this epitope.
Discordance between the kinetics of responses to coin-
cident antigenic challenge is again apparent when compar-
ing responses to FLR and QAK, both of which are de-
rived from the same latent cycle antigen, EBNA3A. Thus,
in three of the B8 patients studied, the two responses show
significantly different patterns of expansion and contrac-
tion over time (Table III). Such results contrast with those
seen in model systems such as Listeria monocytogenes infec-
tion of mice, where a synchronous expansion and contrac-
tion of different epitope-specific reactivities occur even
where the source antigens are themselves distinct (53).
These EBV-specific responses have more in common with
recent work on influenza A infection of mice where anti-
gen specificities that were codominant during first virus
challenge and clearance were differentially amplified in re-
sponse to a second challenge (6, 54). The basis of these id-
iosyncratic differences between FLR and QAK responses
in individual IM patients is not understood, but may relate
to the numbers of potentially reactive cells in each individ-
ual’s naive repertoire.
It is worth noting that the present prospective studies
have focused on tetramer staining as the indicator of
epitope-specific populations. It is therefore formally possible
that we have failed to detect CD8  T cells which have
epitope-specific function yet do not react with the tetramer,
possibly as a result of partial T cell receptor down-regula-
tion, as reported in some other systems (55, 56). However,
we do not believe this to be the case. The inability to detect
CLG-specific T cells in almost all acute IM samples was ap-
parent not just from tetramer staining but also from limiting
dilution cloning experiments in vitro (Fig. 1) and from ex
vivo cytotoxicity assays with IM effector populations. In this
latter context we have observed strong lytic epitope-specific
lysis that correlates well with tetramer staining data whereas
we have never detected killing of CLG epitope-loaded tar-
get cells (3, 23; and data not shown). Likewise, the inability
to detect TLD-specific cells in post-IM bleeds by tetramer
staining was matched by the results of Elispot assays of pep-
tide-induced IFN-  release. Indeed the range and relative
size of epitope-specific reactivities detected in post-IM
blood by tetramer staining was consistently confirmed by
such Elispot assays (data not shown).
Finally, we examined the evolution of phenotypic903 Hislop et al.
change within the different epitope-specific populations
over time. Recent work on long term virus carriers (with
no history of IM) has shown that lytic epitope-specific T
cells are heterogeneous in terms of CD45RO versus
CD45RA expression, whereas latent epitope-specific T
cells are uniformly CD45RO RA  and tend to contain
higher percentages of cells in the CCR7  (“central mem-
ory”) compartment (25). Here we show that at the height
of primary infection, both lytic and latent responses display
a uniform phenotype characteristic of activated effector
cells, i.e., CD45RO , CD45RA , and CCR7 . How-
ever, phenotypic differences became apparent within the
first few months post-IM. Compared with latent responses
which tended to remain CD45RO , lytic responses always
showed a greater shift toward CD45RA positivity with
relatively little acquisition of CCR7. Again the extent of
the divergence between the two types of responding popu-
lations was unique to each patient, but in some cases (e.g.,
IM140) it was very marked with unusually large shifts to-
ward CD45RA  status in lytic epitope–specific cells. Inter-
estingly, where we could follow coincident responses
within a single patient, all lytic epitope–specific popula-
tions showed very similar patterns of phenotypic change,
irrespective of the absolute size of these populations; like-
wise, responses to different latent cycle epitopes varied in
size but retained a similar phenotype (largely but not com-
pletely CD45RO , with generally more CCR7 acquisi-
tion) even in instances where a latent epitope response was
as large as that seen to one of the lytic epitopes. This
strongly suggests that the source of the EBV epitope (i.e.,
lytic versus latent) is a more important determinant of phe-
notypic change within an epitope-specific CD8  T cell re-
sponse than the degree of expansion which the responder
population has experienced in vivo. In other human viral
infections, much greater phenotypic switching toward a
CD45RA  phenotype has been observed within the more
highly amplified CD8  response to cytomegalovirus (an-
other persistent herpesvirus; references 57 and 58), than
among the less abundant CD8  response to influenza (59,
60). Our data suggest that these differences may not relate
to the absolute magnitude of these antigen-specific re-
sponses per se but to the identity and/or means of presen-
tation of the antigens involved.
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